Orion
Orion Corporation, commonly referred to as Orion, is a Finnish pharmaceutical company headquartered in Espoo, Finland. Founded in 1917, Orion has established itself as a key player in the pharmaceutical and biotechnology industry, with a strong presence in Europe and beyond. The company focuses on developing innovative medicines and diagnostic products, particularly in the fields of oncology, pain management, and central nervous system disorders. Orion's core offerings include prescription pharmaceuticals and over-the-counter products, distinguished by their commitment to quality and research-driven development. With a robust pipeline of new therapies and a reputation for excellence, Orion has achieved notable milestones, including successful collaborations and a growing international market presence. As a trusted name in healthcare, Orion continues to advance its mission of improving patient outcomes through science and innovation.
DitchCarbon Score
How does Orion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orion's score of 50 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orion's reported carbon emissions
In 2023, Orion Corporation reported total greenhouse gas emissions of approximately 431,404,000 kg CO2e, with Scope 1 emissions at about 5,511,000 kg CO2e and Scope 2 emissions at approximately 8,429,000 kg CO2e. The company has set ambitious climate commitments, aiming for a 70% reduction in absolute Scope 1 and 2 emissions by 2030, using 2023 as the baseline year. Additionally, Orion is targeting carbon neutrality in its operations by 2031. Orion's long-term goal includes achieving net zero emissions across all scopes by 2050. The company also commits that 78% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029. These initiatives reflect Orion's dedication to sustainable practices within the pharmaceutical and biotechnology sector, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 3,740,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 21,685,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000 | 00,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orion is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
